HUTCHMED to Present Research and Development Updates on July 9, 2024

June 24, 2024 by No Comments

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announced today that it will host an R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.

During the event, the senior management team will provide insights into HUTCHMED’s R&D strategy and vision. They will also share updates on several programs from the company’s extensive and innovative pipeline. These programs include the Phase III ESLIM-01 and Phase II/III ESLIM-02 studies of sovleplenib (a Syk inhibitor) for immune thrombocytopenia (“ITP”) and warm antibody autoimmune hemolytic anemia (“wAIHA”), respectively; the surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma (“PDAC”); and the Phase III RAPHAEL study of HMPL-306 (an IDH1/2 inhibitor) for acute myeloid leukemia (“AML”).

The in-person event will take place in Shanghai from 3:00 p.m. to 5:00 p.m. HKT, presented in Chinese (Putonghua). A live webcast will be held simultaneously. Attendance for the in-person event is by invitation only.

An English language webcast will take place from 8:30 p.m. HKT / 8:30 a.m. EDT / 1:30 p.m. BST on Tuesday, July 9, for approximately two hours.

Both webcasts will be live and can be accessed via [link to be inserted]. Investors interested in listening to a webcast should log on before the start time to download any necessary software. A replay of the event will be available shortly after for approximately 90 days.


HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is a commercial-stage, innovative biopharmaceutical company. The company is dedicated to the global discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED employs approximately 5,000 personnel across its companies, including a team of approximately 1,800 in oncology/immunology. Since its inception, HUTCHMED has focused on bringing cancer drug candidates from its internal discovery processes to patients worldwide. The company has three oncology drugs currently marketed in China, with the first also being marketed in the U.S. For more information, please visit: [link to be inserted] or follow us on [link to be inserted].

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Investor Enquiries +852 2121 8200 /
Media Enquiries  
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) /
Zhou Yi, Brunswick +852 9783 6894 (Mobile) /
Nominated Advisor  
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon +44 (20) 7886 2500